In particular, we aimed to establish: (i) if exogenous ABA could reduce hyperglycemia in multiple low-dose streptozotocin (STZ)-treated mice (i.e., in the presence of markedly reduced endogenous insulin), and (ii) whether ABA could improve the action of suboptimal doses of insulin in single high-dose STZ-treated mice (i.e., in the absence of endogenous insulin). This evidence concerns the gene INS and Hyperglycemia.